Andembry (Garadacimab-Gxii) Patent Expiration, LOE Window & CMS Spending

Andembry (Garadacimab-Gxii) by Csl Behring: Biologic BLA (PHS Act / Purple Book), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $57,100 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCsl Behring
FDA Application & PathwayB761367 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (PHS Act / Purple Book)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($57,100 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.